Sotera Health (SHC) Projected to Post Quarterly Earnings on Friday

Sotera Health (NASDAQ:SHC) is projected to post its Q2 2025 quarterly earnings results before the market opens on Friday, August 8th. Analysts expect Sotera Health to post earnings of $0.17 per share and revenue of $275.81 million for the quarter.

Sotera Health Stock Performance

Shares of NASDAQ:SHC opened at $11.06 on Thursday. Sotera Health has a 12 month low of $9.53 and a 12 month high of $17.08. The company has a market cap of $3.14 billion, a price-to-earnings ratio of 138.27 and a beta of 1.81. The company has a 50-day moving average price of $11.62 and a 200-day moving average price of $12.05. The company has a current ratio of 2.46, a quick ratio of 2.19 and a debt-to-equity ratio of 5.55.

Hedge Funds Weigh In On Sotera Health

Hedge funds have recently modified their holdings of the company. Acadian Asset Management LLC boosted its stake in shares of Sotera Health by 125.5% during the 1st quarter. Acadian Asset Management LLC now owns 25,192 shares of the company’s stock worth $293,000 after acquiring an additional 14,018 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Sotera Health by 14.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 342,934 shares of the company’s stock worth $3,999,000 after acquiring an additional 43,471 shares during the period. Finally, Empowered Funds LLC increased its stake in shares of Sotera Health by 11.1% during the first quarter. Empowered Funds LLC now owns 28,512 shares of the company’s stock worth $332,000 after purchasing an additional 2,845 shares in the last quarter. Institutional investors own 91.03% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on SHC. Piper Sandler decreased their target price on Sotera Health from $15.00 to $13.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 23rd. Wall Street Zen upgraded Sotera Health from a “hold” rating to a “buy” rating in a research note on Saturday, June 28th. Barclays decreased their price target on Sotera Health from $15.00 to $13.00 and set an “overweight” rating on the stock in a research note on Tuesday, June 24th. Finally, The Goldman Sachs Group upgraded shares of Sotera Health from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $14.00 to $17.00 in a research note on Monday, May 5th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Sotera Health has an average rating of “Moderate Buy” and an average target price of $16.00.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.